Phase 1 Single Centre, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of Plant-based H5 VLP (Virus-like Particles), (H5N1) Pandemic Influenza Vaccine Adjuvanted With Aluminium Hydroxide and Administered to Healthy Adults 18-60 Years of Age.

Trial Profile

Phase 1 Single Centre, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of Plant-based H5 VLP (Virus-like Particles), (H5N1) Pandemic Influenza Vaccine Adjuvanted With Aluminium Hydroxide and Administered to Healthy Adults 18-60 Years of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2011

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Aluminium hydroxide
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Sponsors Medicago
  • Most Recent Events

    • 05 Jan 2011 Results recently published in the peer-reviewed journal PLoS ONE, according to a Medicago media release
    • 14 May 2010 Final phase I data reported in a Medicago media release.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed, according to a Medicago media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top